Selective Anti-Herpesvirus Agents
Antiviral Chemistry and Chemotherapy · 2013-06 · 23 (3) · 93-101
DOI: 10.3851/imp2533 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Antiviral Chemistry and Chemotherapy, online erschienen am 01.06.2013. Verfasst von Erik De Clercq. Beteiligte Einrichtung: Rega Institute for Medical Research, KU Leuven, Leuven, Belgium. erik.declercq@rega.kuleuven.be. Die Arbeit wurde bisher 78-mal zitiert (Crossref) und nennt 63 Literaturangaben.
Abstract (Originalsprache)
This review article focuses on the anti-herpesvirus agents effective against herpes simplex virus, varicella-zoster virus and cytomegalovirus, which have either been licensed for clinical use (idoxuridine, trifluridine, brivudin, acyclovir, valaciclovir, valganciclovir, famciclovir and foscarnet) or are under clinical development (CMX001 [the hexadecyloxypropyl prodrug of cidofovir], the helicase-primase inhibitor BAY 57–1293 [now referred to as AIC316], FV-100 [the valine ester of Cf 1743] and the terminase inhibitor letermovir [AIC246]).
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Rega Institute for Medical Research, KU Leuven, Leuven, Belgium. erik.declercq@rega.kuleuven.be.
Zitieren
APA
De Clercq, E. (2013). Selective Anti-Herpesvirus Agents. Antiviral Chemistry and Chemotherapy, 23(3), 93-101. https://doi.org/10.3851/imp2533
Vancouver
De Clercq E. Selective Anti-Herpesvirus Agents. Antiviral Chemistry and Chemotherapy. 2013;23(3):93-101. doi:10.3851/imp2533
BibTeX
@article{DeClercq2013,
author = {De Clercq, Erik},
title = {Selective Anti-Herpesvirus Agents},
journal = {Antiviral Chemistry and Chemotherapy},
year = {2013},
volume = {23},
number = {3},
pages = {93--101},
doi = {10.3851/imp2533}
}
EUVIMED